biote (NASDAQ:BTMD – Get Free Report) and IM Cannabis (NASDAQ:IMCC – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation and institutional ownership.
Profitability
This table compares biote and IM Cannabis’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
biote | 4.30% | -36.67% | 12.50% |
IM Cannabis | -28.03% | -75.51% | -24.18% |
Insider & Institutional Ownership
21.7% of biote shares are owned by institutional investors. Comparatively, 7.7% of IM Cannabis shares are owned by institutional investors. 13.9% of biote shares are owned by company insiders. Comparatively, 5.9% of IM Cannabis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Volatility and Risk
Valuation & Earnings
This table compares biote and IM Cannabis’ top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
biote | $185.36 million | 2.62 | $3.32 million | $0.11 | 71.18 |
IM Cannabis | $36.15 million | 0.14 | -$7.04 million | ($4.80) | -0.46 |
biote has higher revenue and earnings than IM Cannabis. IM Cannabis is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent recommendations for biote and IM Cannabis, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
biote | 0 | 0 | 5 | 0 | 3.00 |
IM Cannabis | 0 | 0 | 0 | 0 | N/A |
biote currently has a consensus price target of $8.11, suggesting a potential upside of 3.58%. Given biote’s higher possible upside, equities research analysts clearly believe biote is more favorable than IM Cannabis.
Summary
biote beats IM Cannabis on 13 of the 13 factors compared between the two stocks.
About biote
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.
About IM Cannabis
IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.
Receive News & Ratings for biote Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for biote and related companies with MarketBeat.com's FREE daily email newsletter.